| | Publication Year | Title | Author(s) |
| 1 | Aug-2023 | The prognostic impact of t(11;14) in multiple myeloma: A real-world analysis from the Australian Lymphoma Leukaemia Group (ALLG) and the Australian Myeloma and Related Diseases Registry (MRDR). | Lim, Kenneth Jc; Wellard, Cameron; Talaulikar, Dipti; Tan, Joanne Lc; Loh, Joanna; Puvanakumar, Pratheepan; Kuzich, James A; Ho, Michelle; Murphy, Matthew; Zeglinas, Nicole; Low, Michael Sy; Routledge, David; Lim, Andrew Boon Ming ; Gibbs, Simon D; Quach, Hang; Morgan, Sue; Moore, Elizabeth; Ninkovic, Slavisa |
| 2 | Jun-2023 | Predictors and outcomes of dose reduction of methotrexate and cyclosporin graft-versus-host disease prophylaxis following allogeneic haemopoietic cell transplantation. | Ramanan, Radha; Lim, Andrew Boon Ming ; Tan, Joanne L C; Barmanray, Rahul D; Mason, Kate; Collins, Jenny; Hillman, Matthew; Szer, Jeff; Bajel, Ashish; Ritchie, David |
| 3 | 2023 | Augmented ICE in Patients With Poor-Risk Refractory and Relapsed Lymphomas. | Loo, Sun; Lim, Andrew Boon Ming ; Lee, Sze Ting ; Grigg, Andrew P |
| 4 | 2-Jun-2022 | Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma: IKEMA subgroup analysis. | Facon, Thierry; Moreau, Philippe; Martin, Thomas G; Spicka, Ivan; Oriol, Albert; Koh, Youngil; Lim, Andrew Boon Ming ; Mikala, Gabor; Rosiñol, Laura; Yağci, Münci; Cavo, Michele; Yong, Kwee; Risse, Marie-Laure; Asset, Gaëlle; Schwab, Sandrine; Martinez, Gracia |
| 5 | May-2022 | Impact of a policy to improve the management of oral medications when patients are fasting before a procedure: an interrupted time series analysis. | To, The-Phung ; Braat, Sabine; Lim, Andrew Boon Ming ; Brien, Jo-Anne; Heland, Melodie J ; Hardidge, Andrew J ; Story, David A |
| 6 | Sep-2021 | The association of mobilising regimen on immune reconstitution and survival in myeloma patients treated with bortezomib, cyclophosphamide and dexamethasone induction followed by a melphalan autograft. | Rees, Matthew J ; Mollee, Peter; Ng, Jun Yen; Murton, Alex; Gonsalves, Jose Filipe; Panigrahi, Ashish; Beer, Hayley; Loh, Joanna; Nguyen, Philip; Hunt, Sam; Jina, Hayden; Wayte, Rebecca; Sutrave, Gaurav; Tan, Jocelyn; Abeyakoon, Chathuri; Chee, Ashlyn; Augustson, Bradley; Kalro, Akash; Lee, Cindy; Agrawal, Shivam; Churilov, Leonid ; Chua, Chong Chyn ; Lim, Andrew Boon Ming ; Zantomio, Daniela ; Grigg, Andrew P |
| 7 | 20-Feb-2021 | Prognostic performance of qSOFA in oncology patients admitted to the emergency department with suspected infection. | Koh, Tze Lui ; Canet, Emmanuel; Amjad, Sobia; Bellomo, Rinaldo ; Taylor, David McD ; Gan, Hui K ; Marhoon, Nada ; Lim, Andrew Boon Ming ; Ong, Wee Loon ; Krishnan, Vivek; Khor, Richard |
| 8 | Sep-2019 | Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial. | Usmani, Saad Zafar; Schjesvold, Fredrik; Oriol, Albert; Karlin, Lionel; Cavo, Michele; Rifkin, Robert M; Yimer, Habte Aragaw; LeBlanc, Richard; Takezako, Naoki; McCroskey, Robert Donald; Lim, Andrew Boon Ming ; Suzuki, Kenshi; Kosugi, Hiroshi; Grigoriadis, George; Avivi, Irit; Facon, Thierry; Jagannath, Sundar; Lonial, Sagar; Ghori, Razi Uddin; Farooqui, Mohammed Z H; Marinello, Patricia; San-Miguel, Jesus |